Valproate for the treatment of acute bipolar depression

Systematic review and meta-analysis

L. A. Smith, V. R. Cornelius, J. M. Azorin, G. Perugi, E. Vieta, A. H. Young, C. L. Bowden

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Background: Our aim was to analyse existing data on the efficacy and tolerability of valproate for the treatment of acute bipolar depression. Methods: Randomized controlled trials comparing valproate with placebo were identified using searches of electronic databases in October 2008. Outcomes investigated were depression, anxiety, hypomania, attrition, and adverse events. Trial quality was assessed, and data were summarized using meta-analyses. Results: Four randomized, controlled, doubleblind trials of 142 participants were included. Trial quality was good, although individual study sample sizes were small. Study duration was six weeks (2 studies) and eight weeks (2 studies). Meta-analysis showed a significant difference in favour of valproate for reduction in depressive symptoms, both on depression symptom scales (standardized mean difference (SMD) - 0.35 (95% confidence interval, - 0.69, - 0.02)), and participants with at least 50% improvement in symptoms - relative risk (RR) 2.00 (1.13, 3.53). Effects on anxiety symptoms were small, SMD - 0.32 (- 0.72, 0.08) and inconclusive (p = 0.12). No evidence of a difference in mania symptoms, withdrawal for any reason, lack of effectiveness or adverse events was detected. Nausea occurred more frequently with valproate compared with placebo though the difference was not significant, RR 2.01 (0.98, 4.11). Other adverse events occurring more frequently with valproate (somnolence, fatigue/muscle weakness, headache, diarrhoea and dry mouth) did not differ significantly between treatment groups. Limitations: Sample sizes were small warranting a larger study to confirm or disprove these findings. Conclusions: Valproate is effective for the reduction of depressive symptoms of acute bipolar depression, and was well tolerated.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalJournal of Affective Disorders
Volume122
Issue number1-2
DOIs
StatePublished - Apr 2010

Fingerprint

Valproic Acid
Bipolar Disorder
Meta-Analysis
Depression
Sample Size
Therapeutics
Anxiety
Randomized Controlled Trials
Placebos
Substance Withdrawal Syndrome
Muscle Weakness
Nausea
Fatigue
Headache
Mouth
Diarrhea
Databases
Confidence Intervals

Keywords

  • Bipolar depression
  • Efficacy
  • Meta-analysis
  • Systematic review
  • Tolerability
  • Valproate

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Smith, L. A., Cornelius, V. R., Azorin, J. M., Perugi, G., Vieta, E., Young, A. H., & Bowden, C. L. (2010). Valproate for the treatment of acute bipolar depression: Systematic review and meta-analysis. Journal of Affective Disorders, 122(1-2), 1-9. https://doi.org/10.1016/j.jad.2009.10.033

Valproate for the treatment of acute bipolar depression : Systematic review and meta-analysis. / Smith, L. A.; Cornelius, V. R.; Azorin, J. M.; Perugi, G.; Vieta, E.; Young, A. H.; Bowden, C. L.

In: Journal of Affective Disorders, Vol. 122, No. 1-2, 04.2010, p. 1-9.

Research output: Contribution to journalArticle

Smith, LA, Cornelius, VR, Azorin, JM, Perugi, G, Vieta, E, Young, AH & Bowden, CL 2010, 'Valproate for the treatment of acute bipolar depression: Systematic review and meta-analysis', Journal of Affective Disorders, vol. 122, no. 1-2, pp. 1-9. https://doi.org/10.1016/j.jad.2009.10.033
Smith, L. A. ; Cornelius, V. R. ; Azorin, J. M. ; Perugi, G. ; Vieta, E. ; Young, A. H. ; Bowden, C. L. / Valproate for the treatment of acute bipolar depression : Systematic review and meta-analysis. In: Journal of Affective Disorders. 2010 ; Vol. 122, No. 1-2. pp. 1-9.
@article{59fbc846f8784a8fa5655e7805adc03e,
title = "Valproate for the treatment of acute bipolar depression: Systematic review and meta-analysis",
abstract = "Background: Our aim was to analyse existing data on the efficacy and tolerability of valproate for the treatment of acute bipolar depression. Methods: Randomized controlled trials comparing valproate with placebo were identified using searches of electronic databases in October 2008. Outcomes investigated were depression, anxiety, hypomania, attrition, and adverse events. Trial quality was assessed, and data were summarized using meta-analyses. Results: Four randomized, controlled, doubleblind trials of 142 participants were included. Trial quality was good, although individual study sample sizes were small. Study duration was six weeks (2 studies) and eight weeks (2 studies). Meta-analysis showed a significant difference in favour of valproate for reduction in depressive symptoms, both on depression symptom scales (standardized mean difference (SMD) - 0.35 (95{\%} confidence interval, - 0.69, - 0.02)), and participants with at least 50{\%} improvement in symptoms - relative risk (RR) 2.00 (1.13, 3.53). Effects on anxiety symptoms were small, SMD - 0.32 (- 0.72, 0.08) and inconclusive (p = 0.12). No evidence of a difference in mania symptoms, withdrawal for any reason, lack of effectiveness or adverse events was detected. Nausea occurred more frequently with valproate compared with placebo though the difference was not significant, RR 2.01 (0.98, 4.11). Other adverse events occurring more frequently with valproate (somnolence, fatigue/muscle weakness, headache, diarrhoea and dry mouth) did not differ significantly between treatment groups. Limitations: Sample sizes were small warranting a larger study to confirm or disprove these findings. Conclusions: Valproate is effective for the reduction of depressive symptoms of acute bipolar depression, and was well tolerated.",
keywords = "Bipolar depression, Efficacy, Meta-analysis, Systematic review, Tolerability, Valproate",
author = "Smith, {L. A.} and Cornelius, {V. R.} and Azorin, {J. M.} and G. Perugi and E. Vieta and Young, {A. H.} and Bowden, {C. L.}",
year = "2010",
month = "4",
doi = "10.1016/j.jad.2009.10.033",
language = "English (US)",
volume = "122",
pages = "1--9",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Valproate for the treatment of acute bipolar depression

T2 - Systematic review and meta-analysis

AU - Smith, L. A.

AU - Cornelius, V. R.

AU - Azorin, J. M.

AU - Perugi, G.

AU - Vieta, E.

AU - Young, A. H.

AU - Bowden, C. L.

PY - 2010/4

Y1 - 2010/4

N2 - Background: Our aim was to analyse existing data on the efficacy and tolerability of valproate for the treatment of acute bipolar depression. Methods: Randomized controlled trials comparing valproate with placebo were identified using searches of electronic databases in October 2008. Outcomes investigated were depression, anxiety, hypomania, attrition, and adverse events. Trial quality was assessed, and data were summarized using meta-analyses. Results: Four randomized, controlled, doubleblind trials of 142 participants were included. Trial quality was good, although individual study sample sizes were small. Study duration was six weeks (2 studies) and eight weeks (2 studies). Meta-analysis showed a significant difference in favour of valproate for reduction in depressive symptoms, both on depression symptom scales (standardized mean difference (SMD) - 0.35 (95% confidence interval, - 0.69, - 0.02)), and participants with at least 50% improvement in symptoms - relative risk (RR) 2.00 (1.13, 3.53). Effects on anxiety symptoms were small, SMD - 0.32 (- 0.72, 0.08) and inconclusive (p = 0.12). No evidence of a difference in mania symptoms, withdrawal for any reason, lack of effectiveness or adverse events was detected. Nausea occurred more frequently with valproate compared with placebo though the difference was not significant, RR 2.01 (0.98, 4.11). Other adverse events occurring more frequently with valproate (somnolence, fatigue/muscle weakness, headache, diarrhoea and dry mouth) did not differ significantly between treatment groups. Limitations: Sample sizes were small warranting a larger study to confirm or disprove these findings. Conclusions: Valproate is effective for the reduction of depressive symptoms of acute bipolar depression, and was well tolerated.

AB - Background: Our aim was to analyse existing data on the efficacy and tolerability of valproate for the treatment of acute bipolar depression. Methods: Randomized controlled trials comparing valproate with placebo were identified using searches of electronic databases in October 2008. Outcomes investigated were depression, anxiety, hypomania, attrition, and adverse events. Trial quality was assessed, and data were summarized using meta-analyses. Results: Four randomized, controlled, doubleblind trials of 142 participants were included. Trial quality was good, although individual study sample sizes were small. Study duration was six weeks (2 studies) and eight weeks (2 studies). Meta-analysis showed a significant difference in favour of valproate for reduction in depressive symptoms, both on depression symptom scales (standardized mean difference (SMD) - 0.35 (95% confidence interval, - 0.69, - 0.02)), and participants with at least 50% improvement in symptoms - relative risk (RR) 2.00 (1.13, 3.53). Effects on anxiety symptoms were small, SMD - 0.32 (- 0.72, 0.08) and inconclusive (p = 0.12). No evidence of a difference in mania symptoms, withdrawal for any reason, lack of effectiveness or adverse events was detected. Nausea occurred more frequently with valproate compared with placebo though the difference was not significant, RR 2.01 (0.98, 4.11). Other adverse events occurring more frequently with valproate (somnolence, fatigue/muscle weakness, headache, diarrhoea and dry mouth) did not differ significantly between treatment groups. Limitations: Sample sizes were small warranting a larger study to confirm or disprove these findings. Conclusions: Valproate is effective for the reduction of depressive symptoms of acute bipolar depression, and was well tolerated.

KW - Bipolar depression

KW - Efficacy

KW - Meta-analysis

KW - Systematic review

KW - Tolerability

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=77649340367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649340367&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2009.10.033

DO - 10.1016/j.jad.2009.10.033

M3 - Article

VL - 122

SP - 1

EP - 9

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 1-2

ER -